We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 504

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Court finds AstraZeneca patent to esomeprazole (nexium) invalid for lack of sound prediction and obviousness

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • September 9 2010

This was an application brought by AstraZeneca under the provisions of the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a notice of compliance to Apotex for 20 and 40 mg esomeprazole magnesium tablets until after the expiry of Canadian Patent No. 2,139,653 (the ‘653 patent

"Grave consequences" defence may be asserted against a generic in a Section 8 action under the PM(NOC) regulations

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • September 14 2010

In an action brought by Apotex Inc. (Apotex) to recover damages under section 8 of the Patented Medicines (Notice of Compliance) Regulations (SOR93-133) (Regulations) in respect of the medicine modafinil, Shire Canada Inc. (Shire) brought this motion for leave to amend its statement of defence, alleging two new defences

Apotex v. Pfizer, motion to strike part of a defence pertaining to res judicata, sildenafil citrate, June 11, 2010

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • July 16 2010

Apotex applied to impeach Pfizer's patent for Viagra and Pfizer defended alleging, in part, res judicata

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

Apotex Inc. v. Pfizer Ireland Pharmaceuticals (2010 FC 968)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 27 2010

Apotex appealed an Order of Prothonotary Aalto dismissing a motion to strike parts of Pfizer’s Statement of Defence relating to res judicata, estoppel (issue and collateral), comity and abuse of process

Summary judgment for impeachment action of Viagra patent upheld by FCA

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • January 24 2014

On January 22, 2014 the Federal Court of Appeal ("FCA") in Pfizer Ireland Pharmaceuticals v Apotex Inc, dismissed an appeal from the judgment of the

Supreme Court of Canada: VIAGRA patent "void" for insufficient disclosure

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • November 8 2012

The Supreme Court of Canada today released the hotly anticipated decision in Teva Canada Limited v Pfizer Canada Inc, 2012 SCC 60 (sildenafil, VIAGRA

Merck-Frosst Schering Pharma GP v. Teva Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 29 2010

The Federal Court granted a prohibition order, holding that Teva's allegation that the patent at issue was obvious was not justified

Supreme Court amends earlier decision: Viagra patent not void

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • June 6 2013

In Teva Canada Ltd v Pfizer Canada Inc, the Supreme Court of Canada (the "SCC") held Pfizer's Canadian Patent No. 2,163,446 (the '446 Patent) to be